Skye Bioscience, Inc. — Director's Dealing 2018

Oct 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2018-10-10

Reporting Person: HEPPELL JAMES L (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-10	Director Stock Option (Right to Buy)	$0.305	A	200000	Acquired	2028-10-10	Common Stock (200000)	Direct

Footnotes

F1: The option will vest in equal monthly installments over a one-year period commencing on the date of grant.